Sidsel Rødgaard-Hansen1, Alexis St George2, Konstantin Kazankov3, Adrian Bauman4, Jacob George2, Henning Grønbæk3, Holger Jon Møller1. 1. a Department of Clinical Biochemistry , Aarhus University Hospital , Aarhus , Denmark. 2. b Storr Liver Centre, Westmead Institute for Medical Research , University of Sydney and Westmead Hospital , Australia. 3. c Department of Hepatology and Gastroenterology , Aarhus University Hospital , Aarhus , Denmark. 4. d Centre for Physical Activity and Health, School of Public Health , Sydney University , Australia.
Abstract
OBJECTIVE: Liver macrophages play an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Soluble CD163 (sCD163), a macrophage-specific biomarker, reflects disease activity in the range of liver diseases. The impact of lifestyle intervention on sCD163 in adult NAFLD patients has not been investigated. MATERIAL AND METHODS: We assessed 126 NAFLD patients participating in a lifestyle intervention study for sCD163 concentrations at baseline, after the three-month intervention period, and at long-term follow-up after 12 and 24 months. RESULTS: The median sCD163 concentration at baseline was 2.59 mg/L (IQR = 1.78-3.63 mg/L). There was a significant decrease in sCD163 from baseline to three months follow-up (-0.64 mg/L, p < .001) with no difference between the four study groups (p = .6). At 12 and 24 months follow-up, the sCD163 concentrations had returned to baseline level (p = .3 and p = .1). Baseline sCD163 correlated with liver biomarkers and metabolic variables. There was a significantly greater decrease in sCD163 in patients who had a decrease in alanine aminotransferase (ALT) compared with patients with unchanged or increased ALT (-0.76 mg/L vs. -0.41 mg/L, p = .02), and in patients with a decrease in HOMA-IR compared with individuals with no decrease (-0.86 mg/L vs. -0.55 mg/L, p = .03). CONCLUSION:sCD163 is associated with markers of liver necro-inflammation and glucose homoeostasis in NAFLD. Participation in a lifestyle intervention programme resulted in a significant reduction in sCD163. Our data support the utility of sCD163 as a biomarker for monitoring the efficacy of therapeutic interventions in NAFLD.
RCT Entities:
OBJECTIVE: Liver macrophages play an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Soluble CD163 (sCD163), a macrophage-specific biomarker, reflects disease activity in the range of liver diseases. The impact of lifestyle intervention on sCD163 in adult NAFLD patients has not been investigated. MATERIAL AND METHODS: We assessed 126 NAFLD patients participating in a lifestyle intervention study for sCD163 concentrations at baseline, after the three-month intervention period, and at long-term follow-up after 12 and 24 months. RESULTS: The median sCD163 concentration at baseline was 2.59 mg/L (IQR = 1.78-3.63 mg/L). There was a significant decrease in sCD163 from baseline to three months follow-up (-0.64 mg/L, p < .001) with no difference between the four study groups (p = .6). At 12 and 24 months follow-up, the sCD163 concentrations had returned to baseline level (p = .3 and p = .1). Baseline sCD163 correlated with liver biomarkers and metabolic variables. There was a significantly greater decrease in sCD163 in patients who had a decrease in alanine aminotransferase (ALT) compared with patients with unchanged or increased ALT (-0.76 mg/L vs. -0.41 mg/L, p = .02), and in patients with a decrease in HOMA-IR compared with individuals with no decrease (-0.86 mg/L vs. -0.55 mg/L, p = .03). CONCLUSION: sCD163 is associated with markers of liver necro-inflammation and glucose homoeostasis in NAFLD. Participation in a lifestyle intervention programme resulted in a significant reduction in sCD163. Our data support the utility of sCD163 as a biomarker for monitoring the efficacy of therapeutic interventions in NAFLD.
Authors: Rasmus Hvidbjerg Gantzel; Mikkel Breinholt Kjær; Tea Lund Laursen; Konstantin Kazankov; Jacob George; Holger Jon Møller; Henning Grønbæk Journal: Front Med (Lausanne) Date: 2021-01-08
Authors: Rocío Gallego-Durán; Rocío Montero-Vallejo; Douglas Maya-Miles; Ana Lucena; Franz Martin; Javier Ampuero; Manuel Romero-Gómez Journal: Front Immunol Date: 2021-11-24 Impact factor: 7.561
Authors: Elisabeth De Smit; Samuel W Lukowski; Lisa Anderson; Anne Senabouth; Kaisar Dauyey; Sharon Song; Bruce Wyse; Lawrie Wheeler; Christine Y Chen; Khoa Cao; Amy Wong Ten Yuen; Neil Shuey; Linda Clarke; Isabel Lopez Sanchez; Sandy S C Hung; Alice Pébay; David A Mackey; Matthew A Brown; Alex W Hewitt; Joseph E Powell Journal: BMC Med Genomics Date: 2018-07-23 Impact factor: 3.063
Authors: João P Magalhães; Diana A Santos; Inês R Correia; Megan Hetherington-Rauth; Rogério Ribeiro; João F Raposo; Andreia Matos; Manuel D Bicho; Luís B Sardinha Journal: Cardiovasc Diabetol Date: 2020-10-07 Impact factor: 9.951